Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma
Journal of Nuclear Medicine · 2023-12 · 64 (12) · 1865-1868
DOI: 10.2967/jnumed.123.266044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 26.10.2023. Verfasst von Christina Laschinsky und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Essen, Essen, Germany; christina.laschinsky@uk-essen.de. Hauptthemen laut MEDLINE: Telomerase, Carcinoma, Papillary, Thyroid Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
The onset of radioiodine-refractory thyroid carcinoma (RR-TC) is a negative predictor of survival and has been linked to the presence of BRAFV600E mutations in papillary thyroid cancer. We aimed to identify further genetic alterations associated with RR-TC.
Methods
We included 38 patients with papillary thyroid cancer who underwent radioiodine imaging and 18F-FDG PET/CT after total thyroidectomy. The molecular profile was assessed by next-generation sequencing. The time to the onset of RR-TC for different genetic alterations was compared using the log-rank test.
Results
The median onset to RR-TC was 0.7 and 19.8 mo in patients with and without, respectively, telomerase reverse transcriptase promoter mutations (P = 0.02) and 1.7 and 19.8 mo in patients with and without, respectively, a tumor protein 53 mutation (P < 0.01). This association was not observed for BRAFV600E mutations (P = 0.49).
Conclusion
Our data show a significant association between the onset of RR-TC and mutations in telomerase reverse transcriptase promoter and tumor protein 53, indicating the need for a more extensive diagnostic workup in these patients. Certain genetic changes put patients with thyroid cancer at risk of developing cancer spread that does not respond to radioiodine therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, University Hospital Essen, Essen, Germany; christina.laschinsky@uk-essen.de.
- German Cancer Consortium, Partner Site Essen, Essen, Germany.
- Institute of Pathology, University Hospital Essen, Essen, Germany.
- Department of Surgery, Section of Endocrine Surgery, Essen University Hospital, Essen, Germany; and.
- Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.
- Department of Endocrinology, Diabetes, and Metabolism, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Zitieren
APA
Laschinsky, C., Theurer, S., Herold, T., Rawitzer, J., Weber, F., Herrmann, K., Brandenburg, T., Führer-Sakel, D., Fendler, W. P., & Weber, M. (2023). Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma. Journal of Nuclear Medicine, 64(12), 1865-1868. https://doi.org/10.2967/jnumed.123.266044
Vancouver
Laschinsky C, Theurer S, Herold T, Rawitzer J, Weber F, Herrmann K, et al. Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma. Journal of Nuclear Medicine. 2023;64(12):1865-1868. doi:10.2967/jnumed.123.266044
BibTeX
@article{Laschinsky2023,
author = {Laschinsky, Christina and Theurer, Sarah and Herold, Thomas and Rawitzer, Josefine and Weber, Frank and Herrmann, Ken and Brandenburg, Tim and Führer-Sakel, Dagmar and Fendler, Wolfgang P and Weber, Manuel},
title = {Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma},
journal = {Journal of Nuclear Medicine},
year = {2023},
volume = {64},
number = {12},
pages = {1865--1868},
doi = {10.2967/jnumed.123.266044}
}
EUVIMED